Tiptree Advisors LLC Makes New $5.68 Million Investment in Eli Lilly and Company (NYSE:LLY)

Tiptree Advisors LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 7,360 shares of the company's stock, valued at approximately $5,682,000. Eli Lilly and Company comprises 5.9% of Tiptree Advisors LLC's holdings, making the stock its 5th biggest position.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new position in Eli Lilly and Company during the 4th quarter worth $8,551,000. LifeWealth Investments LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $354,000. Capital A Wealth Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter valued at $63,000. LM Advisors LLC raised its position in Eli Lilly and Company by 25.7% during the fourth quarter. LM Advisors LLC now owns 6,138 shares of the company's stock worth $4,739,000 after acquiring an additional 1,254 shares during the last quarter. Finally, Lakeshore Capital Group Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $779,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Trading Up 1.5%

Shares of LLY stock traded up $11.03 on Tuesday, reaching $724.74. 3,786,668 shares of the stock were exchanged, compared to its average volume of 3,623,076. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock has a market cap of $686.86 billion, a P/E ratio of 61.89, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The firm has a 50 day moving average of $786.82 and a two-hundred day moving average of $802.40. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Eli Lilly and Company's revenue was up 45.2% on a year-over-year basis. During the same period last year, the firm posted $2.58 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of analyst reports. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their price target for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Truist Financial boosted their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Citigroup lowered their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a report on Tuesday, January 28th. Finally, Wall Street Zen raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.